Markintel™ Pulse Report – August 2025

 

Report Table of Contents

 

Report Metadata

• Title: APAC AI‑assisted Medical Imaging Market — Markintel™ Pulse
• Series / Publisher: Markintel™ Pulse | Marketstrat Inc.
• Pages: 102 | Market Data Tables: 37 | Charts & Visuals: 43
• Price : Individual: $2495 | Team: $3495 | Enterprise: $4495
• Coverage window: Base year 2023; forecast 2024–2032 (current‑year USD).
• Scope:
  • Modalities (CT, MRI, X‑ray/DR, Ultrasound, PET/Nuclear);
  • Clinical areas (Oncology, Neurology/Stroke, Cardiology, Respiratory/Lung, MSK/Ortho, General);
  • Applications (Improved Diagnostic Accuracy & Classification, Efficiency & Data Handling (Workflow), Early Detection & Abnormality, Prognosis & Treatment (Precision), Image Enhancement & Dose Optimization, Segmentation & Feature Extraction, Integration Across Modalities);
  • Revenue streams (Hardware, Software, Service, Cloud/Pay‑per‑Use);
  • End‑use (Hospitals, Imaging Centers, Clinics, Teleradiology, Other);
  • AI Technology (Deep Learning, Computer Vision, Machine Learning, NLP, Robotics, Expert Systems).
  • Forecasts (2023-2032): China, Japan, India, South Korea, Australia, Rest of Asia-Pacific (ROAPAC)
• What’s inside (APAC‑only frameworks & tools):
  • GTM Growth & Maturity — APAC vendor map; Regulatory Velocity; OEM AI Attach Rate; GTM Readiness Radar; Country tiered landscapes & timelines (China, Japan, India, South Korea, ANZ, ROAPAC).
• Methodology & QA: Dual‑lens (top‑down funnel + bottom‑up attach‑rate engine) with a documented QA loop (reconciliation, regulatory diffs, evidence freshness, ASP sanity).
• Format: PDF (analyst narrative, charts, country breakouts).

 

Why This Report

APAC is the fastest‑growing region in AI imaging, moving from ~US$0.61B (2023) to ~US$7.3B (2032)—about 31% CAGR—and overtakes Europe before decade‑end. Buyers need region‑specific evidence, attach‑rate ladders, and country GTM tools to move from pilots to scale; this Pulse report delivers exactly that, in one region‑focused volume.

 

Who Should Buy

• Imaging OEMs, PACS/VNA and cloud vendors building APAC bundles and tenders
• AI pure‑plays localizing modules and pricing for China, India, ASEAN, Japan/Korea, and ANZ
• Provider networks (hospital groups, teleradiology hubs) planning enterprise “AI store” rollouts
• Investors and channel partners vetting evidence, regulatory velocity and GTM maturity

 

Buyer Benefits

• Country‑by‑country sizes & CAGRs (2023→2032) to set realistic revenue targets and prioritize China/India vs. premium Tier‑1 markets.
• Actionable GTM frameworks (Growth & Maturity, Readiness Radar, Channel×Pricing, Country‑Cluster pods) that convert insight into sales motions.
• Procurement & hosting guidance (NMPA/PMDA/MFDS/TGA/HSA/CDSCO; data‑residency norms) to shorten security reviews and avoid refiling traps.
• Attach‑rate ladders & ASP bands by modality to package the right OEM bundle vs. cloud usage offer.
• Competitive signals (OEM bundling, pure‑play momentum) to shape partnership and marketplace strategies.

 

Snapshots & Takeaways

• APAC growth arc: ~US$0.61B → ~US$7.3B (2023–2032), ~31% CAGR; APAC’s share of the global market nears 30% by 2032.
• Where revenue concentrates: CT/MR remain the core; fastest unit‑scale comes from POCUS ultrasound and low‑bandwidth DR in India/ASEAN; PET/Nuclear grows off oncology theranostics.
• Clinical engines: Oncology, Neurology (stroke), and Cardiology together deliver ~75% of absolute growth to 2032.
• Shift in revenue mix: Hardware share declines as fleets modernize; Software + Cloud/Pay‑per‑Use expand fastest (enterprise suites in JP/KR/ANZ; pay‑per‑study in India/ASEAN).
• Attach‑rate baseline: CT ~10% → rising with OEM bundles; MR ~8%; DR ~6%; retrofit dominates incremental dollars as the installed base upgrades.
• What to act on in 12 months: File top modules per market (NMPA/PMDA/MFDS/TGA/HSA/CDSCO), pre‑validate on local clouds (data residency), lead with AI‑recon + stroke triage (JP/KR/ANZ) and DR chest/echo AI pay‑per‑study (India/ASEAN).ompetitive & Partnership Landscape

Competitve & Partnership Landscape

• Global OEMs: GE, Siemens, Philips, Canon, United Imaging embed “AI‑keys” in new CT/MR; capture equipment‑linked replacements but slower in cloud roll‑outs.
• Regional AI Specialists:
  • China: Infervision, Deepwise, VoxelCloud – state tenders, export to MEA.
  • India:ai, Synapsica – cost‑optimized cloud & TB grants.
  • Korea/Japan: Lunit, VUNO, Airdoc – CE+FDA dual filings, strong oncology focus.
• Tech Titans: Alibaba Cloud ET‑Medical, Google Cloud Healthcare, AWS HealthLake – offer GPU credits + data‑residency guarantees to accelerate pilot adoption.
• Teleradiology Hubs: Singapore‑based TeleIM, India’s 5C Networks, Australia’s Everlight – de‑risk entry for vendors by aggregating rural volumes.

Regulatory/Policy

• China (NMPA): Formal AI‑SaMD classification principles remain the primary reference; device regulation refreshed in late‑2024/Jan‑2025 clarifies oversight and speeds innovative pathways.
• Japan (PMDA/MHLW): PMDA Science Board AI‑SaMD report consolidates expectations; two‑step SaMD scheme + PACMP/IDATEN supports lifecycle changes; Japan hosts IMDRF chair/secretariat in 2025.
• South Korea (MFDS): Active guidance on AI clinical trial design; in 2025 MFDS published LLM‑focused guidance for AIMD—relevant to reporting/coding assistants.
• Australia (TGA): Updated software‑based medical devices guidance remains the operative playbook for SaMD/AI approvals.
• Singapore (HSA): Digital‑health program and AI‑MD good practices—useful for cloud‑first deployments and change management alignment.
• India (CDSCO/ABDM): CDSCO’s SaMD classification aligned with IMDRF remains in force; ABDM scale (ABHA, HFR, HPR, linked records) strengthens the case for cloud/usage models.
• Japan reimbursement signal: Academic/clinical literature notes hospital reimbursement for AI diagnostic support when safety‑management standards are met—useful in value dossiers.

Companies Mentioned

Global OEM / Platform vendors

• GE HealthCare, Siemens Healthineers, Philips, Canon Medical, Fujifilm, United Imaging (incl. United Imaging Intelligence), Samsung Medison, Mindray, Alpinion.

AI pure‑plays (regional & global)

• Lunit, VUNO, Infervision, Deepwise, VoxelCloud, Shukun Technology, Keya Medical, 12 Sigma, Huiyihuiying, Yitu Healthcare, DeepNoid (China JV), Airdoc, Synyi AI, Grainevo, Eagle Mind, Qure.ai, DeepTek, Synapsica, Annalise.ai, Aidoc, RapidAI, Viz.ai, Cleerly, ScreenPoint Medical (Transpara), GLEAMER, Brainomix, MaxQ AI, Oxipit, JLK, Radiobotics, Nanox AI / Zebra‑Med, Brainlab.

Marketplaces / PACS / Orchestration

• Sectra (Amplifier Marketplace), Blackford, INFINITT, Neusoft, CARPL.ai, NTT Data, NEC.

Cloud & data platforms

• AWS (incl. HealthLake), Microsoft Azure, Google Cloud Healthcare, Alibaba Cloud, Tencent (AIMIS), Naver Cloud.

Teleradiology & aggregators (APAC examples)

• Everlight Radiology, 5C Networks, TeleIM, Medica.

Methodology & QA

Forecasts reconcile top‑down APAC totals to the global rollup and bottom‑up attach‑rate flows by modality (shipments, installed‑base upgrades, factory vs. retrofit attach, and local ASP bands). The APAC model is anchored by regulatory lines NMPA / PMDA / MFDS / TGA / HAS / CDSCO), ABDM digital‑health rails for India, and peer‑reviewed RWE. A four‑point QA loop checks reconciliation variance (≤0.5%), regulatory‑count deltas, evidence freshness, and ASP sanity for each country/modality.

 

Table of Contents

SECTION 1 – EXECUTIVE SUMMARY. 13

The 25-second Read. 13

Size & Pace (Who Contributes What by 2032). 13

Where Growth Concentrates. 13

Country/Cluster Snapshots. 14

APAC Watchlist (What to Act on in the Next 12 months). 14

Pulse Quick Actions (12 Months). 14

SECTION 2 – RESEARCH METHODOLOGY. 15

Objective. 15

Dual-lens Architecture. 15

APAC-specific Evidence & Inputs. 16

Model Calibration Choices (APAC). 16

Limitations & Mitigations (APAC). 17

Quality Assurance Loop. 17

SECTION 3 – ASIA-PACIFIC (APAC) MARKET. 18

Size, Trajectory & Strategic Importance. 18

Demand Drivers & Headwinds. 18

Competitive & Partnership Landscape. 18

Strategic Clustering & Go-to-Market Nuances. 19

Strategic Recommendations. 19

Regulatory / Policy (What’s New or Clarified). 19

AI Imaging Market by Country – APAC. 20

Markintel GTM Growth and Maturity Matrix – APAC. 21

Competitive Data Set – APAC. 21

Numbers-in-Context – APAC. 23

Strategic Takeaways – APAC. 23

Growth & Maturity Highlights – APAC. 23

M&A Watchlist – APAC. 24

Regulatory Velocity – APAC. 24

OEM AI Attach Rate – APAC. 25

Attach‐Rate Trends – APAC. 25

Factory vs Retrofit Attach. 26

GTM at-a-Glance – APAC. 27

GTM Readiness Radar – APAC. 27

Tiered Customer Landscape – APAC. 27

GTM Timeline – APAC. 28

Adjacency Opportunity Matrix – APAC. 28

Country-Cluster Framework – APAC. 28

White Space Partner Framework – APAC. 29

Regulatory Funding Heatmap – APAC. 30

Channel x Pricing Matrix – APAC. 30

Fast Strategic Cues – APAC. 30

SECTION 4 – CHINESE MARKET. 31

China – Market Overview & Strategic Summary (2023‑2032). 31

Urban–Rural Duality Matters. 31

Strategic Takeaways. 31

Chinese Market Forecasts (2023-2032). 32

Chinese Market by Clinical Area (2023-2032). 32

Chinese Market by Modality (2023-2032). 33

Chinese Market by Revenue Stream (2023-2032). 34

Chinese Market by Clinical Application (2023-2032). 34

Chinese Market by End-Use Organization (2023-2032). 35

Chinese Market by AI Technology (2023-2032). 36

Markintel Growth Maturity Matrix – China AI in Medical Imaging. 37

Executive Commentary. 37

Cross-Quadrant Insights & Tactical Guidance. 39

Priority Recommendations (next 18 months). 39

Competitive Dataset – China. 39

Markintel Ecosystem Collaboration Matrix – China. 40

Decoding the 2 × 2 and Turning it into Action. 40

Three Rules for Winning the Collaboration Game. 41

Quick‑hit Actions for BD teams (Next Two Quarters). 41

Markintel Solution Adoption and Growth Matrix – China. 42

Translating the Matrix into Action. 42

Execution Priorities by Function. 43

“First‑100-Days” Checklist. 43

Metrics that Matter. 44

Operating Roadmap Takeaway. 44

GTM at a Glance – China. 45

GTM Readiness Radar – China. 45

Tiered Customer Landscape – China. 45

GTM Timeline – China. 46

Adjacency-Opportunity Radar – China. 46

Regulatory Funding Heatmap – China. 47

Channel × Pricing Matrix – China. 47

White Space Partnership Matrix – China. 48

SECTION 5 – JAPANESE MARKET. 49

Market Overview & Strategic Summary: Japan. 49

Strategic Outlook. 49

Action Points. 49

Japanese Market Forecasts (2023-2032). 50

Japanese Market by Clinical Area (2023-2032). 50

Japanese Market by Modality (2023-2032). 50

Japanese Market by Clinical Application (2023-2032). 51

Japanese Market by End-Use Organization (2023-2032). 52

Japanese Market by AI Technology (2023-2032). 52

Markintel Solution Adoption & Growth Matrix – Japan. 53

Turning the Matrix into an Operating Road‑Map for Japan (2024‑28). 53

Markintel Ecosystem Collaboration Matrix – Japan. 54

Turning the Matrix into an Operating Roadmap. 55

Playbook Highlights by Quadrant. 55

Risk Checkpoints & Mitigations. 56

Go-to-Market (GTM) Playbook – Japan. 57

GTM Readiness Radar – Japan. 57

Tiered Customer Landscape – Japan. 57

GTM Timeline – Japan. 58

Adjacency Opportunity Radar – Japan. 58

Regulatory Funding Heatmap – Japan. 59

Channel x Pricing Matrix – Japan. 59

White Space Partnership Matrix – Japan. 60

Fast Strategic Cues. 60

SECTION 6 – INDIAN MARKET. 61

Market Overview & Analysis. 61

Market Mechanics. 61

Constraint Map. 61

Competitive Temperature. 62

Actionable Opportunities (2024-26 Window). 62

Go‑Forward Recommendations (by player type). 62

What Success Looks Like. 62

Indian Market Forecasts (2023-2032). 63

Indian Market by Clinical Area (2023-2032). 63

Indian Market by Modality (2023-2032). 63

Indian Market by Revenue Stream (2023-2032). 64

Indian Market by Clinical Application (2023-2032). 64

Indian Market by End-Use Organization (2023-2032). 65

Indian Market by AI Technology (2023-2032). 65

Markintel Solution Adoption & Growth Matrix – India. 66

Solution Classes and Action Cues. 67

Strategic Interpretation & Operating Roadmap. 67

One-Page Operating Checklist. 68

Markintel Ecosystem Collaboration Matrix – India. 69

Operating Roadmap: Leveraging India’s Collaboration Matrix. 69

Strategic Sequencing (2024‑27). 70

Execution Tips. 71

Key Metrics to Track. 71

Competitive Landscape – India. 71

Operating Roadmap. 73

GTM at a Glance – India. 74

GTM Readiness Radar – India. 74

Tiered Customer Landscape – India. 74

GTM Timeline – India. 75

Adjacency-Opportunity Radar – India. 75

Regulatory x Funding Heatmap – India. 76

White-Space Partnership Matrix. 76

Channel × Pricing Matrix. 76

Fast Strategic Cues (Do‑This‑First). 76

SECTION 7 – SOUTH KOREAN MARKET. 77

Market Summary & Overview: South Korea. 77

Key Market Dynamics. 77

Strategic Takeaways. 77

Top 3 Recommendations. 78

South Korea Market Context. 78

South Korean Market Forecasts (2023-2032). 80

South Korean Market by Clinical Area (2023-2032). 80

South Korean Market by Modality (2023-2032). 80

South Korean Market by Revenue Stream (2023-2032). 81

South Korean Market by Clinical Application (2023-2032). 81

South Korean Market by End-Use Organization Type (2023-2032). 82

South Korean Market by AI Technology (2023-2032). 82

GTM at a Glance – South Korea. 83

Six-Pillar GTM Readiness Radar – South Korea. 83

Tiered Customer Landscape – South Korea. 84

Five-Step GTM Timeline – South Korea. 84

Adjacency-Opportunity Radar – South Korea. 85

Regulatory x Funding Heatmap – South Korea. 85

Whitespace Partnership Matrix – South Korea. 86

Channel × Pricing Matrix – Typical 2025 Deals. 86

Fast Strategic Cues. 86

SECTION 8 – AUSTRALIAN MARKET. 87

Market Overview & Analysis. 87

Market Structure & Growth Drivers. 87

Segment Hotspots (Qualitative Sizing). 87

Competitive Landscape. 88

Strategic Implications & GTM Priorities. 88

Action-Oriented Recommendations (Next 12 Months). 88

Australian Market Forecasts (2023-2032). 89

Australian Market by Clinical Area (2023-2032). 89

Australian Market by Modality (2023-2032). 89

Australian Market by Revenue Stream (2023-2032). 90

Australian Market by Clinical Application (2023-2032). 91

Australian Market by End-Use Organization (2023-2032). 91

Australian Market by AI Technology (2023-2032). 92

GTM at a Glance – Australia. 93

GTM Readiness Radar – Australia. 93

GTM Timeline – Australia. 94

Adjacency-Opportunity Radar – Australia. 94

Regulatory x Funding Heatmap. 95

SECTION 9 – REST OF ASIA-PACIFIC (ROAPAC) MARKET. 96

Market Overview & Analysis. 96

Regional Clusters. 96

Market Dynamics ― What’s Shaping Buying Decisions. 96

Actionable Recommendations. 97

Quick-Hit Opportunities by Cluster. 97

What Success Looks Like. 98

Rest of Asia-Pacific Market Forecasts (2023-2032). 98

Rest of Asia-Pacific (ROAPAC) Market by Clinical Area (2023-2032). 98

Rest of Asia-Pacific (ROAPAC) Market by Modality (2023-2032). 99

Strategic Insights. 99

Rest of Asia-Pacific (ROAPAC) Market by Revenue Stream (2023-2032). 99

Rest of Asia-Pacific (ROAPAC) Market by Clinical Application (2023-2032). 100

Rest of Asia-Pacific (ROAPAC) Market by End-Use Organization (2023-2032). 100

Rest of Asia-Pacific (ROAPAC) Market by AI Technology (2023-2032). 101

GTM at a Glance – ROAPAC. 102

GTM Readiness Heatmap – ROAPAC Clusters. 102

Five-Step GTM Roll‑Out Timeline (2024‑2029) – Keyed to Clusters. 102

 

List of Tables

Table 1: AI Imaging Market by Country – APAC (2023—2032, USD Mill). 20

Table 2: Chinese Market by Clinical Area (2023-2032, USD Million). 32

Table 3: Chinese Market by Modality (2023-2032, USD Million). 33

Table 4: Chinese Market by Revenue Stream (2023-2032, USD Million). 34

Table 5: Chinese Market by Clinical Application (2023-2032, USD Million). 34

Table 6: Chinese Market by End-Use Organization (2023-2032, USD Million). 35

Table 7: Chinese Market by AI Technology (2023-2032, USD Million). 36

Table 8: Japanese Market by Clinical Area (2023-2032, USD Million). 50

Table 9: Japanese Market by Modality (2023-2032, USD Million). 50

Table 10:  Japanese Market by Revenue Stream (2023-2032, USD Million). 51

Table 11: Japanese Market by Clinical Application (2023-2032, USD Million). 51

Table 12: Japanese Market by End-Use Organization (2023-2032, USD Million). 52

Table 13: Japanese Market by AI Technology (2023-2032, USD Million). 52

Table 14: Indian Market by Clinical Area (2023-2032, USD Million). 63

Table 15: Indian Market by Modality (2023-2032, USD Million). 63

Table 16: Indian Market by Revenue Stream (2023-2032, USD Million). 64

Table 17: Indian Market by Clinical Application (2023-2032, USD Million). 64

Table 18: Indian Market for AI in Medical Imaging by End-Use Organization (2023-2032, USD Million). 65

Table 19: Indian Market for AI in Medical Imaging by AI Technology (2023-2032, USD Million). 65

Table 20: South Korean Market by Clinical Area (2023-2032, USD Million). 80

Table 21: South Korean Market by Modality (2023-2032, USD Million). 80

Table 22: South Korean Market by Revenue Stream (2023-2032, USD Million). 81

Table 23: South Korean Market by Clinical Application (2023-2032, USD Million). 81

Table 24: South Korean Market End-Use Organization Type (2023-2032, USD Million). 82

Table 25: South Korean Market by AI Technology (2023-2032, USD Million). 82

Table 26: Australian Market by Clinical Area (2023-2032, USD Million). 89

Table 27: Australian Market by Modality (2023-2032, USD Million). 89

Table 28: Australian Market by Revenue Stream (2023-2032, USD Million). 90

Table 29:Australian Market by Clinical Application (2023-2032, USD Million). 91

Table 30: Australian Market by End-Use Organization (2023-2032, USD Million). 91

Table 31: Australian Market by AI Technology (2023-2032, USD Million). 92

Table 32: Rest of Asia-Pacific (ROAPAC) Market by Clinical Area (2023-2032, USD Million). 98

Table 33: Rest of Asia-Pacific (ROAPAC) Market by Modality (2023-2032, USD Million). 99

Table 34: Rest of Asia-Pacific (ROAPAC) Market by Revenue Stream (2023-2032, USD Million). 99

Table 35: Rest of Asia-Pacific (ROAPAC) Market by Clinical Application (2023-2032, USD Million). 100

Table 36: Rest of Asia-Pacific (ROAPAC) Market by End-Use Organization (2023-2032, USD Million). 100

Table 37: Rest of Asia-Pacific (ROAPAC) Market by AI Technology (2023-2032, USD Million). 101

 

List of Figures

Figure 1: APAC Top-Down Funnel – Country Group Mix (2023 vs 2032). 15

Figure 2: Bottom-up Attach Rate Flow APAC (Illustrative). 16

Figure 3: APAC Evidence — Markintel Regional Model 16

Figure 4: Markintel GTM Growth and Maturity Matrix – APAC. 21

Figure 5: Regulatory Velocity – APAC. 24

Figure 6: OEM AI Attach Rate – APAC. 25

Figure 7: AI Revenue Split – Factory vs Retrofi t – APAC. 26

Figure 8: GTM Readiness Radar – APAC. 27

Figure 9: Tiered Customer Landscape – APAC (2032). 27

Figure 10: GTM Timeline – APAC (2024-29). 28

Figure 11: Regulatory Funding Heatmap – APAC. 30

Figure 12: Markintel Growth Maturity Matrix – China AI in Medical Imaging. 37

Figure 13: Markintel Ecosystem Collaboration Matrix – China. 40

Figure 14: Markintel Solution Adoption and Growth Matrix – China. 42

Figure 15: GTM Readiness Radar – China. 45

Figure 16: Tiered Customer Landscape – China (2032). 45

Figure 17: GTM Timeline – China (2024-29). 46

Figure 18: Adjacency-Opportunity Radar – China. 46

Figure 19: Regulatory Funding Heatmap – China. 47

Figure 20: Markintel Solution Adoption & Growth Matrix – Japan. 53

Figure 21: Markintel Ecosystem Collaboration Matrix – Japan. 54

Figure 22: GTM Readiness Radar – Japan. 57

Figure 23: GTM Timeline – Japan. 58

Figure 24: Adjacency Opportunity Radar – Japan. 58

Figure 25: Regulatory Funding Heatmap – Japan. 59

Figure 26: White Space Partnership Matrix – Japan. 60

Figure 27: Markintel Solution Adoption & Growth Matrix – India. 66

Figure 28: Markintel Ecosystem Collaboration Matrix – India. 69

Figure 29: GTM Readiness Radar – India. 74

Figure 30: Tiered Customer Landscape – India. 74

Figure 31: GTM Timeline – India. 75

Figure 32: Adjacency-Opportunity Radar – India. 75

Figure 33: Regulatory x Funding Heatmap – India. 76

Figure 34: Six-Pillar GTM Readiness Radar – South Korea. 83

Figure 35: Tiered Customer Landscape – South Korea. 84

Figure 36: Five-Step GTM Timeline – South Korea. 84

Figure 37: Adjacency-Opportunity Radar – South Korea. 85

Figure 38: Regulatory x Funding Heatmap – South Korea. 85

Figure 39: GTM Readiness Radar – Australia. 93

Figure 40: GTM Timeline – Australia. 94

Figure 41: Adjacency-Opportunity Radar – Australia. 94

Figure 42: Regulatory x Funding Heatmap. 95

Figure 43: GTM Readiness Heatmap – ROAPAC Clusters. 102

Figure 44: Five-Step GTM Roll Out Timeline (2024 2029) – ROAPAC. 102